Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SSTR4 | P31391 | 18/20 | 0.50 |
| ▸ | SSTR1 | P30872 | 4/20 | 0.47 |
| ▸ | NOS2 | P35228 | 1/20 | 0.44 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24260505 | 0.87 | SSTR4 (0.48) | SSTR4SSTR1NOS2MKNK2 | |
| SCHEMBL24260259 | 0.81 | SSTR4 (0.46) | SSTR4SSTR1 | |
| SCHEMBL24260196 | 0.77 | SSTR4 (0.43) | SSTR4SSTR1NOS2MKNK2 | |
| SCHEMBL26897468 | 0.70 | PRKCQ (0.38) | SSTR4 | |
| SCHEMBL24260213 | 0.69 | CYP3A4 (0.44) | SSTR4SSTR1NOS2 | |
| SCHEMBL24260224 | 0.69 | ELANE (0.45) | — | |
| SCHEMBL24260258 | 0.69 | KDM4E (0.49) | SSTR4SSTR1 | |
| SCHEMBL25011515 | 0.68 | JAK2 (0.47) | NOS2 | |
| SCHEMBL30271396 | 0.68 | JAK2 (0.47) | NOS2 | |
| SCHEMBL27897385 | 0.68 | OPRK1 (0.47) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11820727-B1 | Capsaicinoid prodrug compounds and their use in treating medical conditions | CENTREXION THERAPEUTICS CORPORATION (US) | 2023-11-21 | — | — | US | disclosed |
| US-11820727-B1 | Capsaicinoid prodrug compounds and their use in treating medical conditions | CENTREXION THERAPEUTICS CORPORATION (US) | 2023-11-21 | — | — | US | disclosed |
| US-11254659-B1 | Capsaicinoid prodrug compounds and their use in treating medical conditions | CENTREXION THERAPEUTICS CORPORATION (US) | 2022-02-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11820727-B1 | Capsaicinoid prodrug compounds and their use in treating medical conditions | TRPV1, TRPV2, TRPV3 | SSTR4 1067/4885SSTR1 1810/4885NOS2 2202/4885 |
| US-11254659-B1 | Capsaicinoid prodrug compounds and their use in treating medical conditions | TRPV1, TRPA1, TRPV2 | SSTR4 1474/4885SSTR1 1480/4885NOS2 1663/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.